NurExone Biologic to Present Exosome Platform and U.S. Initiatives at NYC Conference

NurExone Biologic Inc. (TSX.V: NRX) (OTCQB: NRXBF) is set to showcase its exosome-based therapeutic platform and development pipeline at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, scheduled for September 9-10 in New York City. The company's co-founder and chairman, Yoram Drucker, will present to investors and engage in one-on-one meetings, highlighting NurExone's advancements in regenerative medicine for central nervous system (CNS) injuries.

The presentation comes at a pivotal time for the biotechnology firm, which is advancing its lead candidate, ExoPTEN, through preclinical programs. ExoPTEN has demonstrated strong potential in treating acute spinal cord and optic nerve damage, offering hope for patients with these debilitating conditions. NurExone's innovative approach leverages exosomes—nanoscale vesicles that facilitate cell-to-cell communication—to deliver therapeutic agents directly to injured tissues, minimizing invasiveness and enhancing efficacy.

A key focus of NurExone's presentation will be its U.S. manufacturing and commercialization initiatives. By anchoring its North American strategy through its Exo-Top platform, the company aims to establish a robust supply chain for quality exosomes and targeted delivery systems. This move is designed to position NurExone for potential clinical development and eventual market entry, aligning with the growing demand for advanced regenerative therapies.

The conference provides a platform for NurExone to connect with investors and industry stakeholders, potentially accelerating its path to clinical trials. The company's participation underscores its commitment to translating preclinical success into viable treatments for CNS injuries, a significant unmet medical need. With limited effective options for conditions like spinal cord injury, NurExone's exosome-based therapies could represent a breakthrough, offering neuroprotective and regenerative benefits.

According to the company, the U.S. market presents substantial opportunities for growth, driven by increasing investment in biotechnology and a favorable regulatory environment for innovative therapies. NurExone's strategic initiatives aim to capitalize on this momentum, ensuring that its therapies are not only developed but also manufactured and commercialized efficiently. The company's focus on quality and scalability will be critical as it prepares for potential clinical development.

Investors attending the conference will gain insights into NurExone's pipeline, including timeline expectations and milestones. The one-on-one meetings with Yoram Drucker offer a chance for deeper discussions on the company's strategy and potential partnerships. NurExone's participation in this event is a testament to its proactive approach in engaging with the investment community and advancing its mission to bring exosome-based therapies to patients.

For more details on the conference and NurExone's presentation, interested parties can view the full press release at https://ibn.fm/o2PD0.